Every day, our field-proven, AI-powered diagnostic solutions help pathologists ensure better cancer care for patients around the world

Trusted

Created by pathologists for pathologists

Proven

Delivering real-world clinical impact

Deployed

The worldwide leader in live clinical rollouts

Chosen

Platform of choice for the world’s leading physicians, health systems and diagnostic solution providers

Ibex Partners with AstraZeneca and Daiichi Sankyo

The companies will validate and bring to market Ibex’s AI-powered biomarker scoring product, allowing pathologists to optimize breast cancer diagnosis and help select patients eligible for HER2-directed therapy.

Read More

The Ibex Difference

  • AI-powered solutions detect cancer and more than a hundred other diagnostic features in multiple tissue types
  • Clinically-proven accuracy, enhanced efficiency and improved user experience
  • Developed from rich datasets extracted from over 10 million slides from multiple pathology institutes
  • Multiple AI algorithms trained by teams of expert pathologists using deep learning technologies
Trusted AI

Why Ibex

Quality

Accurate, timely, personalized cancer diagnosis for every patient

Trust

Higher quality,
more targeted,
high-impact care

Experience

Enhanced physician confidence and patient safety

Outcomes

Faster diagnosis, better user experience and lower pathology workloads

Efficiency

Optimized workflows improve productivity across the cancer pathway

Customers & Partners

The role of AI in pathology and how it impacts cancer care

Prof. Stuart Schnitt from Brigham and Women's Hospital talks about Galen Breast and how its accuracy and broad detection capabilities transform pathologists' work

Watch Now

Experience the future of pathology

Contact Us


    By providing my details I agree to the IBEX Terms and conditions and Privacy policy. I also agree to receive emails from IBEX and I understand that I may opt out of IBEX subscriptions at any time.

    TRUSTED
    CANCER
    DIAGNOSTICS
    FOR ALL